Quantcast

Latest Mammaprint Stories

2010-08-05 07:25:00

IRVINE, California, and AMSTERDAM, August 5, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA.

2010-06-04 06:58:00

HUNTINGTON BEACH, California and AMSTERDAM, June 4, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S.

2010-04-29 10:30:00

HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 /PRNewswire/ -- Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test.

2010-04-20 08:03:00

HUNTINGTON BEACH, California and AMSTERDAM, April 20, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today it has closed an agreement with Ferrer inCode for the commercialization of Agendia's FDA-cleared breast cancer recurrence test MammaPrint in Latin America. For the successful commercialization of MammaPrint, Ferrer inCode will leverage the distribution power of its mother company Grupo Ferrer Internacional, the leading Spanish pharmaceutical...

2010-03-24 12:40:00

New Service to Provide Breast Cancer Molecular Subtyping HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes. This new service is based on an 80-gene signature that identifies...

2010-03-17 11:00:00

12 Cancer Drugs Tested, 20 Leading U.S.

2010-02-09 07:00:00

HUNTINGTON BEACH, California and AMSTERDAM, February 9 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that it has received the Clinical Laboratory Permit from the New York State Department of Health.

2009-12-17 07:15:00

HUNTINGTON BEACH, California and AMSTERDAM, December 17 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages.

2009-12-08 07:30:00

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that it will be presenting six studies focusing on MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium (SABCS), one of the premiere conferences in breast cancer research worldwide.

2009-12-01 07:00:00

HUNTINGTON BEACH, California and AMSTERDAM, December 1 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test.


Word of the Day
bretelles
  • In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.
The word 'bretelles' comes from a French word meaning 'braces'.